Codexis, Inc. (CDXS) Director Buys $39,800.00 in Stock
Codexis, Inc. (NASDAQ:CDXS) Director Patrick Y. Yang bought 10,000 shares of the firm’s stock in a transaction dated Monday, August 21st. The shares were acquired at an average cost of $3.98 per share, with a total value of $39,800.00. Following the completion of the transaction, the director now owns 348,234 shares of the company’s stock, valued at $1,385,971.32. The purchase was disclosed in a legal filing with the SEC, which is available at this link.
Codexis, Inc. (NASDAQ CDXS) traded up $0.25 during trading on Thursday, reaching $6.85. 242,567 shares of the company traded hands, compared to its average volume of 170,228. Codexis, Inc. has a 1-year low of $3.60 and a 1-year high of $7.95.
Several research firms have recently commented on CDXS. Jefferies Group boosted their target price on shares of Codexis from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Friday, October 13th. HC Wainwright boosted their price target on shares of Codexis from $8.00 to $8.50 and gave the stock a “buy” rating in a report on Friday, October 13th. BidaskClub upgraded shares of Codexis from a “sell” rating to a “hold” rating in a report on Saturday, December 2nd. Zacks Investment Research upgraded shares of Codexis from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Finally, ValuEngine upgraded shares of Codexis from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $7.50.
COPYRIGHT VIOLATION NOTICE: This news story was published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/12/07/codexis-inc-cdxs-director-buys-39800-00-in-stock.html.
Codexis Company Profile
Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.
Receive News & Ratings for Codexis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.